CORRECTION article

Front. Immunol., 19 June 2025

Sec. Vaccines and Molecular Therapeutics

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1639717

Correction: Tubeimuside I improves the efficacy of a therapeutic Fusobacterium nucleatum dendritic cell-based vaccine against colorectal cancer

This article is a correction to:

  1. Tubeimuside I improves the efficacy of a therapeutic Fusobacterium nucleatum dendritic cell-based vaccine against colorectal cancer

    1. Read original article
Yanan Tong&#x;Yanan Tong1†Guoxiu Lu&#x;Guoxiu Lu2†Zhiguo WangZhiguo Wang1Shanhu HaoShanhu Hao1Guoxu Zhang*Guoxu Zhang1*Hongwu Sun*Hongwu Sun3*
  • 1Department of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, China
  • 2College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, China
  • 3Department of Microbiology and Biochemical Pharmacy, National Engineering Research Center of Immunological Products, College of Pharmacy, Third Military Medical University, Chongqing, China

A Correction on
Tubeimuside I improves the efficacy of a therapeutic Fusobacterium nucleatum dendritic cell-based vaccine against colorectal cancer

by Tong Y, Lu G, Wang Z, Hao S, Zhang G and Sun H (2023). Front. Immunol. 14:1154818. doi: 10.3389/fimmu.2023.1154818

Author Guoxiu Lu was erroneously assigned to Affiliation 1 Department of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, China. This affiliation has now been removed for author Guoxiu Lu.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: colorectal cancer, F. nucleatum, tubeimuside I, dendritic cells, vaccine

Citation: Tong Y, Lu G, Wang Z, Hao S, Zhang G and Sun H (2025) Correction: Tubeimuside I improves the efficacy of a therapeutic Fusobacterium nucleatum dendritic cell-based vaccine against colorectal cancer. Front. Immunol. 16:1639717. doi: 10.3389/fimmu.2025.1639717

Received: 02 June 2025; Accepted: 03 June 2025;
Published: 19 June 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Tong, Lu, Wang, Hao, Zhang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Guoxu Zhang, emhhbmdndW94dV81MDJAMTYzLmNvbQ==; Hongwu Sun, c3VuaG9uZ3d1MjAwMUAxNjMuY29t

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.